The growing impact of heart failure as a major public health problem (1, 2) has been
paralleled by an intensive search for better understanding and management of this disorder …

Background: The success of β-blocking agents in clinical trials of heart failure (HF) has led to
a widespread call for their increased use, which assumes these agents will perform as well …

BACKGROUND: The success of beta-blocking agents in clinical trials of heart failure (HF)
has led to a widespread call for their increased use, which assumes these agents will …

Heart failure is a deadly disease that has reached epidemic proportions in industrialized
countries. Patients living with heart failure carry a heavy burden in terms of morbidity. Many …

A recent clinical investigation reported by Packer et al1 used a multiplicity of end points to
assess the efficacy of carvedilol for heart failure because the most appropriate measure (s) …

The risk of heart failure increases with age. Prognosis is poor, with 82% of patients dying
within 6 years of diagnosis. As the population ages, heart failure is becoming an increasing …

BACKGROUND: β-Blockers reduce morbidity and mortality rates in heart failure (HF) clinical
trials, but it is unknown whether these findings persist in the community setting. METHODS …

2718 Circulation June 24, 2014 compared with placebo, influenced the outcome of survival.
V-HeFT (Vasodilator–Heart Failure Trial), published in 1986, produced the first glimmer of …

Readers of the Journal of Cardiac Failure are aware of the major advances that have
occurred in the medical treatment of chronic heart failure over the past 2 decades. Perhaps …

Several life-prolonging therapies are available for the treatment of heart failure, yet they are
underutilized in many patients. A treatment gap exists between patients who are eligible for …